YOU'RE INVITED...
A Private First Look: InStat™ by Veristat™ with Ken Getz and Other Industry Leaders
May 18, 2026 | Eddie Merlots | Boston | By invitation only
The TLF bottleneck has been accepted for decades.
On May 18, a small group will see what it looks like when that changes.
Every clinical trial generates data. That data shapes decisions. Those decisions shape what happens next for the study, the submission, and ultimately the patients waiting on the other side of it.
And yet, between database locking and submission-ready tables, figures, and listings, most teams still lose 4 to 6 weeks.
That delay does not just cost time. It compresses review windows, creates pressure late in the study, and pushes critical reporting and submission work further down the line.
On May 18, Veristat is hosting a private dinner in Boston for a small group of clinical development leaders for a first look at a different model.
The evening will open with Ken Getz, Executive Director and Research Professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, followed by a private first look at InStat by Veristat ahead of the public announcement the next morning.
We would love to have you be part of this first group of industry leaders.
Why this dinner matters
Data is only useful when teams can act on it.
For years, the delay between database lock and final TLF delivery has been treated as part of the process. Planned around. Absorbed. Accepted.
But when this stage runs long, the cost shows up everywhere else: less room to review, more last-minute pressure, more back-and-forth, and less visibility at the point where teams need clarity most.
This dinner is for leaders who know that late-stage execution matters, and who want an early look at what changes when one of the most stubborn waits in clinical development is no longer taken for granted.
What guests will experience
A private, pre-announcement first look
-
See the launch before it is announced publicly.
An industry perspective on the cost of delay
-
Hear from Ken Getz on the operational drag that continues to slow clinical development and why it matters.
A live look at a different model
-
See what submission-ready TLF generation looks like when the manual programming step is no longer driving the timeline.
A small room of peers
-
Join a focused table of leaders and operators for a candid conversation, not a ballroom presentation.
The evening
6:00–6:30 PM
Arrive at Eddie Merlots
Cocktails, appetizers, and welcome from the Veristat team
6:30–6:50 PM
Ken Getz
Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
A perspective on the cost of delay in clinical development, why execution gaps persist, and what leaders should be paying closer attention to now.
Dinner is served
7:20–7:40 PM
Mark McBride and Kyle McBride
Why this bottleneck has lasted so long, what has changed, and the introduction of InStat by Veristat
7:40–8:00 PM
Live demonstration
A first look using real clinical study data, followed by open Q&A
8:00–9:00 PM
Dinner continues
Open conversation with invited guests and speakers
Who will be in the room
Ken Getz
Executive Director and Research Professor
Tufts Center for the Study of Drug Development, Tufts University School of Medicine
Kim Boericke
CEO, Veristat
Mark McBride
VP, Biostatistics and Programming
Veristat
Kyle McBride
VP, AI and Innovation
InStat by Veristat
AJ Mills
Executive VP Commercial, Versistat
Request Invite
Seats are Limited
Why Veristat?
© 2026 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.